Live tape
Top 8, mentions 7d11,135GOOGL2,270 mentions▲ +0.03HTZ1,729 mentions▲ +0.10SPCX1,513 mentions▲ +0.08NBIS1,435 mentions▲ +0.10SNDK1,341 mentions▲ +0.11NVDA1,187 mentions▲ +0.09MSFT886 mentions▲ +0.06META774 mentions▲ +0.03

Equity · Healthcare

WST

West Pharmaceutical Services, Inc. · NYSE

$354 +1.65% 1D Finazon · prior-day close · Aug 7, 2026
Price · Chart
Our own end-of-day closes 56 sessions
$380 $300 19 May 7 Aug

The line runs $304.02 on 19 May through $354 on 7 August, on a scale from $300 to $380. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of WST over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 56 sessions over that window: $304.02 on 19 May 2026 through $354 on 7 August 2026.

Market cap $24.9B
P/E (TTM) 45.3
52-week range $231 – $366
Avg volume 220.9K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 17, 2026

WST insider trades

SEC Form 4 · last 90 days · newest Form 4 filing 11 Aug 2026
Open-market buys 0
Open-market sells 0
Non-trade filings 2

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
11 Aug 2026 McMahon Robert W. SVP & Chief Financial Officer Option exercise 7,149
11 Aug 2026 McMahon Robert W. SVP & Chief Financial Officer Tax withheld 3,109 $1.09M

WST reported financials

SEC EDGAR XBRL

WST reported revenue of $3.1B for the fiscal year ended 31 Dec 2025. Net income over the same period was $493.7M.

Figure Reported Period
Revenue $3.1B 31 Dec 2025 fiscal year
Net income $493.7M 31 Dec 2025 fiscal year
Diluted EPS $6.79 31 Dec 2025 fiscal year
Total assets $4.1B 30 Jun 2026 at period end
Total equity $3.0B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

WST earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $2.15 —
31 Mar 2026 Q1 2026 $1.92 —
31 Dec 2025 FY 2025 $6.79 —
30 Sep 2025 Q3 2025 $1.92 —
30 Jun 2025 Q2 2025 $1.82 —
31 Mar 2025 Q1 2025 $1.23 —
31 Dec 2024 FY 2024 $6.69 —
30 Sep 2024 Q3 2024 $1.85 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

WST institutional holders

SEC Form 13F

14 of the 45 institutional funds we track reported a WST position for the quarter ended 30 Jun 2026 — a combined $509.6M; the latest of those filings landed 14 Aug 2026.

Fund Action Shares Value
Bill & Melinda Gates Foundation Trust Held (±25%) 444,500 $159.6M
Citadel Advisors Held (±25%) +9.0% shares 352,769 $126.6M
Point72 Asset Management Added +77.8% shares 283,396 $101.7M
Marshall Wace Added +5,213.3% shares 83,578 $30.0M
AQR Capital Management Trimmed −78.4% shares 57,609 $20.3M
Balyasny Asset Management Added +3,982.6% shares 45,766 $16.4M
Man Group Trimmed −56.5% shares 34,669 $12.4M
Renaissance Technologies Trimmed −85.3% shares 30,900 $11.1M
Tudor Investment Corp Trimmed −63.5% shares 23,851 $8.6M
Millennium Management Added +54.6% shares 21,290 $7.6M

Showing the 10 largest of 14 reported positions. The figures above count all of them.

Source: SEC EDGAR 13F filings

WST fails-to-deliver

SEC CNS data

On 07 Jul 2026, 1 shares of WST failed to deliver (about $358).

Settlement date Shares failed Notional % of shares out
07 Jul 2026 1 $358 <0.001%

Source: SEC fails-to-deliver (CNS) data